1. Home
  2. FBGL vs CARM Comparison

FBGL vs CARM Comparison

Compare FBGL & CARM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FBGL
  • CARM
  • Stock Information
  • Founded
  • FBGL 1996
  • CARM 2016
  • Country
  • FBGL Singapore
  • CARM United States
  • Employees
  • FBGL N/A
  • CARM N/A
  • Industry
  • FBGL Miscellaneous manufacturing industries
  • CARM Biotechnology: Pharmaceutical Preparations
  • Sector
  • FBGL Consumer Discretionary
  • CARM Health Care
  • Exchange
  • FBGL Nasdaq
  • CARM Nasdaq
  • Market Cap
  • FBGL 23.6M
  • CARM 19.7M
  • IPO Year
  • FBGL 2025
  • CARM N/A
  • Fundamental
  • Price
  • FBGL $1.02
  • CARM $0.45
  • Analyst Decision
  • FBGL
  • CARM Hold
  • Analyst Count
  • FBGL 0
  • CARM 5
  • Target Price
  • FBGL N/A
  • CARM $4.57
  • AVG Volume (30 Days)
  • FBGL 1.9M
  • CARM 512.7K
  • Earning Date
  • FBGL 01-01-0001
  • CARM 03-31-2025
  • Dividend Yield
  • FBGL N/A
  • CARM N/A
  • EPS Growth
  • FBGL N/A
  • CARM N/A
  • EPS
  • FBGL 0.04
  • CARM N/A
  • Revenue
  • FBGL $15,607,369.00
  • CARM $20,268,000.00
  • Revenue This Year
  • FBGL N/A
  • CARM $46.34
  • Revenue Next Year
  • FBGL N/A
  • CARM N/A
  • P/E Ratio
  • FBGL $31.33
  • CARM N/A
  • Revenue Growth
  • FBGL 25.78
  • CARM 41.13
  • 52 Week Low
  • FBGL $0.87
  • CARM $0.38
  • 52 Week High
  • FBGL $5.45
  • CARM $2.77
  • Technical
  • Relative Strength Index (RSI)
  • FBGL N/A
  • CARM 44.17
  • Support Level
  • FBGL N/A
  • CARM $0.43
  • Resistance Level
  • FBGL N/A
  • CARM $0.50
  • Average True Range (ATR)
  • FBGL 0.00
  • CARM 0.05
  • MACD
  • FBGL 0.00
  • CARM 0.00
  • Stochastic Oscillator
  • FBGL 0.00
  • CARM 28.16

About CARM Carisma Therapeutics Inc.

CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.

Share on Social Networks: